A Randomised, Double-blind, Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Intranasal RV568 in Healthy Volunteers

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Intranasal RV568 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2016

At a glance

  • Drugs RV 568 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Most Recent Events

    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
    • 22 May 2013 Pharmacodynamic results (cohort 2) presented at the 109th International Conference of the American Thoracic Society.
    • 22 May 2013 Pharmacodynamic results (cohort 1) presented at the 109th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top